Oct 17th 2013 - Edison Investment Research today published a report on Neovacs SA (ALNEV.L, LSE:ALNEV, LON:ALNEV) entitled "Ronta Exit Spells Good News For Neovacs". In summary, the report says:
Roche's decision not to develop rontalizumab, its IFNα monoclonal antibody, any further after completing Phase II trials in systemic lupus erythematosus (SLE) removes a key competitor for Neovacs's IFNα-Kinoid. Roche achieved clinical proof of concept with its IFNα targeted approach, but the compound did not meet economic criteria and thus is removed from the competitive space. Meanwhile, Neovacs has initiated a Phase IIb trial with its lead product TNFα-Kinoid in rheumatoid arthritis (RA) while it seeks a partner. The ability to partner this drug, which has also been in Phase II for Crohn's disease, is central to Neovacs's investment case.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »